Hepatitis C Infection
44
0
1
30
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
16 trials with published results (36%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
15.9%
7 terminated out of 44 trials
81.1%
-5.4% vs benchmark
20%
9 trials in Phase 3/4
53%
16 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 30 completed trials
Clinical Trials (44)
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures
Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)
Interaction Between Paroxetine and Telaprevir
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection
HCV-HIV Co-infected Patient Cohort in Thailand
Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality
Hepatitis C Infection in World Trade Center Responders
Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)